Skyworks Solutions (NasdaqGS:SWKS) 2025 Conference December 02, 2025 04:15 PM ET Company ParticipantsPhilip Brace - CEOConference Call ParticipantsTimothy Arcuri - AnalystTimothy ArcuriAll right, we're going to get started. I'm Timothy Arcuri. I'm the Semi and Semi Equipment Analyst here at UBS, and we're very pleased to have Skyworks next in the agenda. Very pleased to have Phil Brace, who's the CEO of Skyworks. So again, Phil, thank you for the time.Philip BraceThanks, Tim. It's a pleasure to be here, and ...

Cadence Design Systems (NasdaqGS:CDNS) 2025 Conference December 02, 2025 04:15 PM ET Company ParticipantsAnirudh Devgan - CEOConference Call ParticipantsNatalie Winkler - Equity Research AnalystNatalie WinklerHi everybody, my name is Natalie Winkler. I'm a semiconductor analyst here at UBS. I'm very excited to have Anirudh Devgan with us, CEO of Cadence Design Systems. Before we start, I want to read a quick forward-looking statement.Anirudh DevganThese are big chairs, you know.Natalie WinklerToday's discus ...

Tenax Therapeutics (NasdaqCM:TENX) FY Conference December 02, 2025 04:15 PM ET Company ParticipantsChris Giordano - President and CEOStuart Rich - CMOModeratorNext up, we have Chris Giordano and Stuart Rich from Tenax Therapeutics. I'm going to turn it right over to you guys for an introduction of the company, where things stand today. Then we'll come back for some questions.Chris GiordanoGreat, great. Hi, I'm Chris Giordano. Thanks for attending. We're currently enrolling in a U.S. and Canadian phase III t ...

Cellebrite DI (NasdaqGS:CLBT) 2025 Conference December 02, 2025 04:15 PM ET Company ParticipantsSteve Pettigrew - Head of Software Investment BankingTom Hogan - CEODavid Barter - CFOSteve PettigrewGuys, thank you for joining today. My name's Steve Pettigrew. I lead the software investment banking business at UBS. Pleased to have with me today David Barter, Chief Financial Officer, and Tom Hogan, Chief Executive Officer of Cellebrite. For those of you who don't know Cellebrite, the digital investigations mar ...

Open Text (NasdaqGS:OTEX) 2025 Conference December 02, 2025 04:15 PM ET Company ParticipantsTom Jenkins - Executive Chair and Chief Strategy OfficerConference Call ParticipantsSeth Gilbert - AnalystSeth GilbertMy name is Seth Gilbert. I'm one of the SMID software analysts here at UBS. Today we have the honor and the privilege of chatting with Tom Jenkins. Tom was the CEO of OpenText from 1994-2005. Now he's the Chief Strategy Officer and also the Executive Chair of the Board since 1998. So there might be no ...

Outfront Media (NYSE:OUT) 2025 Conference December 02, 2025 04:10 PM ET Company ParticipantsMatt Siegel - CFOConference Call ParticipantsMarlane Pereiro - High-Yield Cable and Media AnalystMarlane PereiroEveryone, and thank you for joining us. My name is Marlane Pereiro. I'm the High-Yield Cable and Media Analyst at Bank of America. I'm happy to have with us this afternoon from OUTFRONT Media, Matt Siegel. Thank you for joining us.Matt SiegelThanks for having me.Marlane PereiroIt's a pleasure. You know, I w ...

Central Garden & Pet Company (NasdaqGS:CENT) 2025 Conference December 02, 2025 04:10 PM ET Company ParticipantsNiko Lahanas - CEOConference Call ParticipantsAndrew Hovanes - AnalystNone - AnalystNone - AnalystNoneAppreciate you all for joining us. My name is Bill Reuter. I cover high-yield consumer products at Bank of America. The first initiation report I ever wrote in 2005 was on Central Garden & Pet Company.Niko LahanasNo way.Yeah, yeah. So this was the beginning of my journey, which has now been a prett ...

Q3 Fiscal 2026 Financial Results December 2, 2025 Forward Looking Statements and Non-GAAP Information This presentation contains forward-looking statements regarding our products, business and operations, including but not limited to our views relating to our future period financial and business results, our opportunity relating to hyperscale and AI environments, our ability to meet hyperscalers' performance, price and other requirements, our ability to expand with our current hyperscale customer and to lan ...

© Okta and/or its affiliates. All rights reserved. © Okta and/or its affiliates. All rights reserved. Confidential Information of Okta – For Recipient's Internal Use Only. Safe Harbor This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our financial outlook, business strategy and plans, market trends and market size, opportunities and positioning. ...

Summary of Supernus Pharmaceuticals FY Conference Call Company Overview - **Company**: Supernus Pharmaceuticals (NasdaqGM:SUPN) - **Event**: 37th Annual Piper Sandler Healthcare Conference - **Date**: December 02, 2025 Key Points Industry and Product Focus - **Product in Focus**: APO-go, a treatment for movement disorders, particularly for patients with advanced Parkinson's disease [1][2] - **Market Demand**: There is significant demand for APO-go, with physicians expressing strong support for the product despite current supply constraints [3][4] Supply Chain Challenges - **Current Situation**: The existing manufacturer is facing capacity issues, unable to meet the overwhelming demand for APO-go [5][6] - **Resolution Efforts**: Supernus is exploring multiple avenues to resolve supply constraints, including discussions with the FDA and potential partnerships with alternative suppliers [2][3][10] - **Timeline for Solutions**: Onboarding a new manufacturer could take several months to a year, depending on regulatory approvals and readiness [7][8][9] Patient Demand and Enrollment - **Patient Enrollment Forms (PEFs)**: Despite supply issues, physicians continue to submit PEFs, indicating ongoing interest in APO-go [14][15] - **Patient Demographics**: Initial demand is primarily from patients with advanced Parkinson's disease who have limited treatment options [19][20] Financial Projections - **Sales Estimates**: Initial peak sales estimates for APO-go are projected between $200 million and $300 million, which may need to be revisited once supply issues are resolved [20][21] - **Long-term Outlook**: The long-term potential for APO-go remains strong, as it offers a unique treatment option not available in the current market [21][22] Competitive Landscape - **Market Competition**: APO-go faces competition from other products like Vyalev and Apokyn, but it serves a different purpose as a rescue medication [25][26] - **Product Differentiation**: APO-go is positioned as a unique treatment option, distinct from traditional therapies like Levodopa [21][22] New Product Developments - **Zurzuvae**: Another product in the portfolio targeting postpartum depression, with significant market potential as it addresses a large unmet need [32][33] - **Sales Strategy**: The sales force is primarily targeting OB-GYNs, with potential for expansion based on market response [34][36] M&A and Future Strategy - **M&A Focus**: Supernus is prioritizing commercial-stage assets and is open to acquiring later-stage development programs [47][48] - **Partnership with Biogen**: There is potential for discussions regarding the buyout of Biogen's 50% stake in Zurzuvae, although both companies are currently committed to the brand [46] Financial Synergies - **Cost Synergies**: Supernus anticipates realizing up to $200 million in annualized synergies from the acquisition of Sage Therapeutics [42] Research and Development - **Early-stage Assets**: Supernus is evaluating early-stage assets from Sage and its own pipeline to determine which programs to advance [43][44] Conclusion Supernus Pharmaceuticals is navigating significant supply chain challenges with its APO-go product while maintaining strong demand and interest from healthcare providers. The company is also expanding its product portfolio with Zurzuvae and exploring strategic M&A opportunities to enhance its market position.